This study plans to treat subjects with pembrolizumab by infusion in combination with radiation therapy to see if the combination is an effective treatment for relapsed/refractory non-Hodgkin lymphoma. Radiation therapy is commonly used to treat relapsed/refractory non-Hodgkin lymphoma. Although pembrolizumab is FDA-approved for some cancers, including Hodgkin lymphoma, it is not currently approved for most non-Hodgkin lymphomas. Your physicians will monitor your cancer’s response to these treatments as well as any side effects you may experience.

You may be eligible for this study if you meet the following criteria:

• Conditions: non Hodgkin lymphoma,
• Age: Between 18 Years - 99 Years
• Gender: All